Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Vacuum Cleaners That Are Not difficult To Use For Home - 2Flu season is just beginning, but doctors are already on high alert
- 3Two Israeli infants among wounded by shrapnel in overnight Iranian missile barrage
- 4The moon and sun figure big in the new year's lineup of cosmic wonders
- 5A top Marine shares his secrets to keeping fit at 50
- The Response to Self-improvement: Embracing a Development Outlook
- 5 Language Learning Applications
- German Winemakers Rewrite The Rules Of Riesling In A Warming World
- Flu cases skyrocket in US. See cases, where people got sick.
- Watch Rocket Lab launch Japanese technology-demonstrating satellite to orbit tonight
- Instructions to Safeguard Your Speculations In the midst of Changing Disc Rates
- Pat Finn, actor from 'The Middle,' dies at 60 after bladder cancer diagnosis
- Colorado residents face earliest water restrictions ever — a harbinger of worse to come
- Between 600 to 800 aid trucks entering Gaza daily since start of ceasefire, COGAT confirms
